A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors

Int J Clin Pharmacol Ther. 2003 Dec;41(12):620-1. doi: 10.5414/cpp41620.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Administration, Oral
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Area Under Curve
  • Aspartate Aminotransferases / pharmacology
  • Benzenesulfonates / administration & dosage
  • Benzenesulfonates / pharmacokinetics*
  • Benzenesulfonates / pharmacology*
  • Doxorubicin / administration & dosage
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / drug therapy
  • Neoplasms / drug therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / administration & dosage
  • Pyridines / pharmacokinetics*
  • Pyridines / pharmacology*
  • Sorafenib
  • Treatment Outcome

Substances

  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Doxorubicin
  • Sorafenib
  • Aspartate Aminotransferases